Oncoinvent (ONCIN)

[Tixis]

Noen som vet noe om mulig rep emi?
Nå så lenge kursen ligger der den ligger så bør d vel være duket for rep emi.
Kommer den så vil vi kanskje se en dropp i kursen i etterkant da noen mindre aktører vil være kjempehappy med 50% avk på disse aksjene.

[hybrid]

Har du kjøpt oncoinvent aksjer etter alle de nanotirader du har hatt på hver eneste bio-tråd?

[Tixis]

Yepp .
Kunne ikke dy meg, men her skal jeg prøve å mene minst mulig eller rettere sagt syte mindre.
Dette føler jeg et lodd som kan gå riktig så bra og har bestemt meg for at om kursen er ditt eller datt så får den bare være det.
Men at potensialet er stort er d vel ingen tvil om.
Skal lese denne tråden fra begynnelsen en dag for å få litt påfyll. Kikket litt og la jo merke til at det var tiden man var veldig positiv til NN, men vet jo hvordan d gikk.
Vel, nok om d.
På hver eneste bio tråd var vel litt drøyt kanskje

[TekBot]

Oncoinvent ASA: Resolution to increase the share capital in connection with subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 22 January 2025
…

Vis børsmeldingen

Reference is made to the stock exchange announcement by Oncoinvent ASA (“Oncoinvent” or the “Company”) on 9 December 2024 regarding an extraordinary general meeting of the Company where it was resolved to increase the share capital of the Company with NOK 5,000,000 by the issuance of 50,000,000 new shares in connection with a private placement of in total 65,000,000 new shares (the “Offer Shares”), each with a nominal value of 0.10, at a subscription price of NOK 2 per Offer Share, resulting in gross proceeds to the Company of 130,000,000(the “Private Placement”).

Further, reference is made to the stock exchange announcement by the Company on 9 December 2024 regarding the board of directors’ resolution to increase the share capital with NOK 1,166,630 by the issuance of 11,666,300 Offer Shares and the stock exchange announcement by the Company on 10 December 2024 regarding the board of directors’ resolution to increase the share capital with NOK 333,370 by the issuance of 3,333,700 Offer Shares in connection with the Private Placement.

In connection with the Private Placement, the Company has considered to carry out a potential subsequent offering of up to 5,500,000 new shares (the “Subsequent Offering”) to reduce the dilutive effects of the Private Placement and also providing eligible shareholders with the opportunity to subscribe for new shares at the same subscription price as that applied in the Private Placement.

On 21 November 2024, the general meeting, inter alia, resolved to grant the board of directors an authorisation to increase the Company’s share capital by up to NOK 1,749,900, by the issuance of new shares. In accordance with this authorisation, the board of directors has today resolved to carry out the Subsequent Offering and to increase the share capital by a minimum of NOK 0.10 and a maximum of NOK 550,000, through the issuance of a minimum of 1 new share and a maximum of 5,500,000 new shares, each with a nominal value of NOK 0.10 and with a subscription price of NOK 2.

The subscription period in the Subsequent Offering will commence on 23 January 2025 at 09:00 hours (CET) and expire on 6 February 2025 at 12:30 hours (CET).

Shareholders of the Company as of 27 November 2024, as registered as such in the Company’s shareholders register in Euronext Securities Oslo, the Norwegian Central Securities Depository (the “ESO”) on 29 November 2024 (the “Record Date”) who at such date held 16,000 or fewer shares, and (i) were not allocated shares in the Private Placement, and (ii) are not resident in a jurisdiction where such offering would be unlawful, or would require any approval, filing, registration or similar action of a registration document or prospectus (such eligible shareholders jointly, the “Eligible Shareholders”) will be granted 4.10340 non-transferable subscription right (“Subscription Right”) for every existing shares registered as held by such Eligible Shareholder in the ESO as at the Record Date, rounded down to the nearest whole Subscription Right. Each Subscription Right gives, subject to applicable law, the right to subscribe for, and be allocated, one (1) new share in the Subsequent Offering at the subscription price of NOK 2. Over-subscription and subscription without subscription rights will be permitted.

Allocation of the new shares in the Subsequent Offering is expected to take place on or about 6 February 2025, and the new shares are expected to be delivered on or about 18 February 2025. Further information regarding the Subsequent Offering is set out in the attached information document.

The Company, in consultation with the Managers (as defined below), reserves the right to cancel the Subsequent Offering at any time at its sole discretion.

Advisors:
Carnegie AS and DNB Markets, a part of DNB Bank ASA are acting as managers in the Subsequent Offering (the “Managers”).

Advokatfirmaet Thommessen AS is acting as legal advisor to the Company. Advokatfirmaet Wiersholm AS is acting as legal advisor to the Managers.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About Oncoinvent
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver powerful radiation directly to cancer cells. The Company’s lead product candidate, Radspherin®, is being advanced through clinical development by a team with experience from all stages of radiopharmaceutical development. Internal manufacturing and supply chain capabilities have been established, which now have the capacity to supply Radspherin® for multi-center phase 2 clinical studies.

For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com

Important information
The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Canada, Japan or the United States (including its territories and possessions, any state of the United States and the District of Columbia). This release is an announcement issued pursuant to legal information obligations. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “US Securities Act”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the US Securities Act.

The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Japan or the United States.

This announcement is an advertisement and is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on prospectuses to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (as amended) as implemented in any Member State.

The issue, subscription or purchase of shares in the Company is subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Managers assume any responsibility in the event there is a violation by any person of such restrictions. The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. The Managers are acting for the Company and no one else in connection with the Subsequent Offering and will not be responsible to anyone other than the Company providing the protections afforded to their respective clients or for providing advice in relation to the Subsequent Offering and/or any other matter referred to in this release.

Forward-looking statements: This release and any materials distributed in connection with this release may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Kilde

[TekBot]

Oncoinvent ASA: Key information relating to subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 22 January 2025
…

Vis børsmeldingen

Reference is made to the stock exchange announcement by Oncoinvent ASA (“Oncoinvent” or the “Company”) earlier today on 22 January 2025 regarding the board of directors resolution to carry out a subsequent offering of up to 5,500,000 new shares in the Company (the “Subsequent Offering”), at a subscription price of NOK 2 (“Subscription Price”), raising gross proceeds of maximum NOK 11,000,000.

The Subsequent Offering will, subject to applicable securities laws, be directed towards shareholders of the Company as of 27 November 2024, as registered as such in the Company’s shareholders register in Euronext Securities Oslo, the Norwegian Central Securities Depository (the “ESO”) on 29 November 2024 (the “Record Date”) who at such date held 16,000 or fewer shares, and (i) were not allocated shares in the Private Placement, and (ii) are not resident in a jurisdiction where such offering would be unlawful, or would require any approval, filing, registration or similar action of a registration document or prospectus (such eligible shareholders jointly the “Eligible Shareholders”).

The subscription period in the Subsequent Offering will commence on 23 January 2025 at 09:00 hours (CET) and expire on 6 February 2025 at 12:30 hours (CET).

In accordance with the continuing obligations of companies listed on Euronext Growth Oslo, the following key information is given with respect to the Subsequent Offering:

Date on which the terms and conditions of the repair issue were announced: 22 January 2025

Last day including right: 27 November 2024

Ex-date: 28 November 2024

Record date: 29 November 2024

Date of approval: 22 January 2025

Maximum number of new shares: 5,500,000 new shares

Subscription price: NOK 2

Other information (optional): Each Eligible Shareholder will be granted 4.10340 subscription rights for each share registered as held by such Eligible Shareholder as of the Record Date. The number of subscription rights granted to each Eligible Shareholder will be rounded down to the nearest whole subscription right. Over-subscription and subscription without subscription rights will be permitted. ISIN for the subscription rights: NO 0013464826. The Company, in consultation with the Managers (as defined below), reserves the right to cancel the Subsequent Offering at any time at its sole discretion.

Advisors:
Carnegie AS and DNB Markets, a part of DNB Bank ASA are acting as managers in the Subsequent Offering (the “Managers”).

Advokatfirmaet Thommessen AS is acting as legal advisor to the Company. Advokatfirmaet Wiersholm AS is acting as legal advisor to the Managers.

This information is published in accordance with the requirements of the Continuing Obligations for companies listed at Euronext Growth Oslo.

About Oncoinvent
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver powerful radiation directly to cancer cells. The Company’s lead product candidate, Radspherin®, is being advanced through clinical development by a team with experience from all stages of radiopharmaceutical development. Internal manufacturing and supply chain capabilities have been established, which now have the capacity to supply Radspherin® for multi-center phase 2 clinical studies.

For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com

Important information
The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Canada, Japan or the United States (including its territories and possessions, any state of the United States and the District of Columbia). This release is an announcement issued pursuant to legal information obligations. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “US Securities Act”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the US Securities Act.

The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Japan or the United States.

This announcement is an advertisement and is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on prospectuses to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (as amended) as implemented in any Member State.

The issue, subscription or purchase of shares in the Company is subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Managers assume any responsibility in the event there is a violation by any person of such restrictions. The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. The Managers are acting for the Company and no one else in connection with the Subsequent Offering and will not be responsible to anyone other than the Company providing the protections afforded to their respective clients or for providing advice in relation to the Subsequent Offering and/or any other matter referred to in this release.

Forward-looking statements: This release and any materials distributed in connection with this release may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Kilde

[urban66]

AI/KI:
Her er hovedpunktene om hvem som kan tegne i den etterfølgende emisjonen (subsequent offering):

Kvalifiserte aksjonærer må oppfylle følgende kriterier:

1. Være aksjonær i Oncoinvent per 27. november 2024
2. Være registrert i VPS per 29. november 2024 (Record Date)
3. Ha eid 16.000 eller færre aksjer på denne datoen
4. IKKE ha fått tildelt aksjer i den private plasseringen
5. IKKE være bosatt i en jurisdiksjon hvor tilbudet ville være ulovlig

Disse kvalifiserte aksjonærene vil få:

• 4,10340 ikke-omsettelige tegningsretter for hver eksisterende aksje de eier
• Hver tegningsrett gir rett til å tegne én ny aksje til tegningskurs NOK 2

Viktige detaljer om emisjonen:

• Tegningsperioden er fra 23. januar 2025 kl 09:00 til 6. februar 2025 kl 12:30
• Det er tillatt med overtegning og tegning uten tegningsretter
• Maksimalt 5,5 millioner nye aksjer skal utstedes
• Tildeling er forventet rundt 6. februar 2025
• Levering av nye aksjer er forventet rundt 18. februar 2025

Selskapet forbeholder seg retten til å kansellere emisjonen når som helst.

[TekBot]

Oncoinvent ASA: Commencement of subscription period for subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 23 January 2025
…

Vis børsmeldingen

Reference is made to the stock exchange announcement by Oncoinvent ASA (“Oncoinvent” or the “Company”) on 22 January 2025 regarding the board of directors resolution to carry out a subsequent offering (the “Subsequent Offering”).

The Subsequent Offering consists of an offer by the Company to issue up to 5,500,000 new shares (the “Offer Shares”), each with a nominal value of NOK 0.10, at a subscription price of NOK 2 per Offer Share (“Subscription Price”), being equal to the subscription price in the private placement in the Company completed on 11 December 2024. Subject to all Offer Shares being issued, the Subsequent Offering will result in NOK 11,000,000 in gross proceeds to the Company.

The subscription period in the Subsequent Offering will commence today, on 23 January 2025 at 09:00 hours (CET) and expire on 6 February 2025 at 12:30 hours (CET).

The Subsequent Offering is, subject to applicable securities laws, directed towards shareholders of the Company as of 27 November 2024, as registered as such in the Company’s shareholders register in Euronext Securities Oslo, the Norwegian Central Securities Depository (the “ESO”) on 29 November 2024 (the “Record Date”) who at such date held 16,000 or fewer shares, and (i) were not allocated shares in the Private Placement, and (ii) are not resident in a jurisdiction where such offering would be unlawful, or would require any approval, filing, registration or similar action of a registration document or prospectus (such eligible shareholders jointly the “Eligible Shareholders”).

Each Eligible Shareholder will be granted 4.10340 non-transferable subscription right (“Subscription Right”) for every existing shares registered as held by such Eligible Shareholder as of the Record Date, rounded down to the nearest whole Subscription Right. Each Subscription Right will, subject to applicable law, give the right to subscribe for, and be allocated, one (1) Offer Share in the Subsequent Offering. Over-subscription and subscription without Subscription Rights will be permitted.

The Subscription Rights must be used to subscribe for Offer Shares prior to expiry of the Subscription Period on 6 February 2025 at 12:30 hours (CET). Subscription Rights that are not used to subscribe for Offer Shares before the expiry of the Subscription Period will have no value and will lapse without compensation to the holder.

The payment date for the Offer Shares will be on or about 11 February 2025. Subject to timely payment of the Offer Shares subscribed for and allocated in the Subsequent Offering, the issuance and delivery of the Offer Shares pertaining to the Subsequent Offering is expected to be completed on or about 18 February 2025 and the Offer Shares are expected to commence trading on Euronext Growth Oslo on or about the same day.

The Company, in consultation with the Managers (as defined below), reserves the right to cancel the Subsequent Offering at any time at its sole discretion.

Advisors:
Carnegie AS and DNB Markets, a part of DNB Bank ASA are acting as managers in the Subsequent Offering (the “Managers”).

Advokatfirmaet Thommessen AS is acting as legal advisor to the Company. Advokatfirmaet Wiersholm AS is acting as legal advisor to the Managers.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About Oncoinvent
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver powerful radiation directly to cancer cells. The Company’s lead product candidate, Radspherin®, is being advanced through clinical development by a team with experience from all stages of radiopharmaceutical development. Internal manufacturing and supply chain capabilities have been established, which now have the capacity to supply Radspherin® for multi-center phase 2 clinical studies.

For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com

Important information
The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Canada, Japan or the United States (including its territories and possessions, any state of the United States and the District of Columbia). This release is an announcement issued pursuant to legal information obligations. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “US Securities Act”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the US Securities Act.

The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Japan or the United States.

This announcement is an advertisement and is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on prospectuses to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (as amended) as implemented in any Member State.

The issue, subscription or purchase of shares in the Company is subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Managers assume any responsibility in the event there is a violation by any person of such restrictions. The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. The Managers are acting for the Company and no one else in connection with the Subsequent Offering and will not be responsible to anyone other than the Company providing the protections afforded to their respective clients or for providing advice in relation to the Subsequent Offering and/or any other matter referred to in this release.

Forward-looking statements: This release and any materials distributed in connection with this release may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Kilde

[urban66]

Synes dette er god og ryddig måte å behandle aksjonærene.
Rep.emi som planlagt fair mot småaksjonærer og bare ca 5% utvanning. La oppturen begynne
Hovedpunkter:

• Tegningsperiode: 23. januar kl 09:00 - 6. februar kl 12:30 2025
• Tilbud: Inntil 5,5 millioner nye aksjer til NOK 2 per aksje
• Bruttoproveny: Maksimalt NOK 11 millioner
• Betalingsdato: Ca. 11. februar 2025
• Levering og notering av nye aksjer: Ca. 18. februar 2025

Bekreftelse av tidligere meldte vilkår:

• For aksjonærer med 16.000 eller færre aksjer per 27. november 2024
• 4,10340 tegningsretter per aksje
• Overtegning og tegning uten tegningsretter er tillatt
• Tegningsrettene kan ikke omsettes og forfaller verdiløse hvis ikke brukt

Selskapet forbeholder seg retten til å kansellere emisjonen.

[JonoOno]

Syns dette er svært lite fair med de av oss som hadde over 16.000 aksjer… det er vel stor sett alle som var med på emisjonen på 10kr…

[Tixis]

Før oppturen starter skal vel d vel først pøses ut med aksjer på 2.2 -2.5 fra de som nå får på 2.
De er nok super happy med 20-30% avkastning.
Først når disse har tømt seg kan oppturen starte.

[Boms]

Tja, folk som satt med aksjer med kostpriser på alt fra 10 til 50+ er vel ikke nødvendigvis så ivrig etter å selge ut på de kursnivåene vi ser nå.

Jeg selger i hvert fall ikke før vi ser hvordan selskapet sine kliniske forsøk utvikler seg videre.

[hybrid]

Ber dere lese nøye.

Overtegning og tegning uten tegningsretter er tillatt

Tegning uten tegningsretter, vil det si at selv de med 16k+ kan tegne?

[pensjonist]

Betyr dette at jeg kan selge mine 10.000 aksjeri dag for kr 2,55 og så tegne meg opp for 40.000 nye til kr 2 pr stk?

[Boms]

Om du ikke vil beholde din relative andel av selskapet, kan du selvsagt selge de aksjene du har og tegne for tegningsrettene. Men du vil altså redusere din andel av selskapet. Du kan nok ikke regne med å få tildeling for annet enn de tegningsrettene du har fått på VPS kontoen, for jeg tror mange overtegner stort. Men det koster jo lite å prøve.

[Merlin]

Dnb med temmelig intetsigende analyse av ellers solide Hollom.

3,50 i kursmål. Så her lønner det seg å bli med på pågående emisjon til 2 kr.

Ingen mening om oppkjøpsverdi eller at behandlingen er svært banebrytende og kan bli en blockbuster.

Det nevnes riktignok at bruken kan utvides til andre områder.

[InVivo]

https://www.fiercepharma.com/pharma/2025-forecast-companies-rush-radiopharmaceuticals-oncology-whats-next?

[TekBot]

Oncoinvent ASA: Grant of share options - mandatory notification of trade

Oncoinvent ASA (“Oncoinvent” or the “Company”) has today granted 3,560,000 share options under its long term share incentive scheme for employees (the “Option Program”), each with a strike price of NOK 2.4991 of these 2,210,000 share options were granted to primary insiders of the Company. For more information about the grant of share options to primary insiders, see the attached forms.

Following today’s grant, a total of 4,789,808 share options have been granted under the Option Program.
…

Vis børsmeldingen

This information is subject to the disclosure requirements pursuant to article 19 of the regulation EU 596/2014 (the EU Market Abise Regulation) and section 5-12 of the Norwegian Securities Trading Act.

About Oncoinvent
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver powerful radiation directly to cancer cells. The Company’s lead product candidate, Radspherin®, is being advanced through clinical development by a team with experience from all stages of radiopharmaceutical development. Internal manufacturing and supply chain capabilities have been established, which now have the capacity to supply Radspherin® for multi-center phase 2 clinical studies.

For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com

Kilde

[hybrid]

Hoho, sier du det du kjære tekbot.

[TekBot]

Oncoinvent ASA: Last day of the subscription period in the subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 6 February 2025
…

Vis børsmeldingen

Reference is made to the stock exchange announcement by Oncoinvent ASA (“Oncoinvent” or the “Company”) on 22 January 2025 regarding the launch of a subsequent offering of up to 5,500,000 new shares (“Offer Shares”) in the Company, each with a nominal value of NOK 0.10, at a subscription price of NOK 2 per Offer Share (the “Subsequent Offering”).

The subscription period for the Subsequent Offering (the “Subscription Period”) will expire today, 6 February 2025 at 12:30 hours (CET).

Correctly completed subscription forms must be received by one of the managers of the Subsequent Offering, Carnegie AS or DNB Markets, a part of DNB Bank ASA (collectively, the “Managers”), or in the case of online subscriptions, be registered before the expiry of the Subscription Period.

Subscription rights that are not used to subscribe for Offer Shares before the expiry of the Subscription Period will have no value and will lapse without compensation to the holder. Over-subscription and subscription without subscription rights is permitted.

Further information about the Subsequent Offering and the subscription procedure is included in an information document that is available at the Managers’ websites: Ongoing prospectuses and offerings: - Carnegie Norway and www.dnb.no/emisjoner.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About Oncoinvent
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver powerful radiation directly to cancer cells. The Company’s lead product candidate, Radspherin®, is being advanced through clinical development by a team with experience from all stages of radiopharmaceutical development. Internal manufacturing and supply chain capabilities have been established, which now have the capacity to supply Radspherin® for multi-center phase 2 clinical studies.

For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com

Important information
The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Canada, Japan or the United States (including its territories and possessions, any state of the United States and the District of Columbia). This release is an announcement issued pursuant to legal information obligations. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “US Securities Act”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the US Securities Act.

The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Japan or the United States.

This announcement is an advertisement and is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on prospectuses to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (as amended) as implemented in any Member State.

The issue, subscription or purchase of shares in the Company is subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Managers assume any responsibility in the event there is a violation by any person of such restrictions. The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. The Managers are acting for the Company and no one else in connection with the Subsequent Offering and will not be responsible to anyone other than the Company providing the protections afforded to their respective clients or for providing advice in relation to the Subsequent Offering and/or any other matter referred to in this release.

Forward-looking statements: This release and any materials distributed in connection with this release may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Kilde

[InVivo]

Nok et oppkjøp/deal innenfor radiofarmaka segmentet. Oppkjøp til potensielt ca 11 milliarder NOK.

https://www.fiercepharma.com/pharma/lantheus-lays-out-250m-get-its-hands-radiopharma-developer-and-cdmo-evergreen?_gl=1